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IMPORTANCE Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in
ischemic stroke; however, many patientsmay have been receiving antiplatelet therapy before
acute ischemic stroke and could face an increased risk for bleedingwhen treatedwith tPA.
OBJECTIVE To assess the risks and benefits associated with prestroke antiplatelet therapy
among patients with ischemic stroke who receive intravenous tPA.
DESIGN, SETTING, AND PARTICIPANTS This observational study used data from the American
Heart Association and American Stroke Association GetWith the Guidelines–Stroke registry,
which included 85 072 adult patients with ischemic stroke who received intravenous tPA in
1545 registry hospitals from January 1, 2009, throughMarch 31, 2015. Data were analyzed
during the same period.
EXPOSURES Prestroke antiplatelet therapy before tPA administration for acute ischemic
stroke.
MAIN OUTCOMES ANDMEASURES Symptomatic intracranial hemorrhage (sICH), in-hospital
mortality, discharge ambulatory status, andmodified Rankin Scale score (range, 0 [no
symptoms] to 6 [death]).
RESULTS Of the 85 072 registry patients, 38 844 (45.7%)were receiving antiplatelet therapy
before admission; 46 228 patients (54.3%)were not. Patients receiving antiplatelet therapy
were older (median [25th-75th percentile] age, 76 [65-84] vs 68 [56-80] years) and had a
higher prevalence of cardiovascular risk factors. The unadjusted rate of sICHwas higher in
patients receiving antiplatelet therapy (5.0%vs 3.7%). After risk adjustment, prior use of
antiplatelet agents remained associatedwith higher odds of sICH comparedwith no use
(adjusted odds ratio [AOR], 1.18 [95%CI, 1.10-1.28]; absolute difference, +0.68% [95%CI,
0.36%-1.01%]; number needed to harm [NNH], 147). Among patients enrolled onOctober 1,
2012, or later, the highest odds (95%CIs) of sICHwere found in 15 116 patients receiving aspirin
alone (AOR, 1.19 [1.06- 1.34]; absolute difference [95%CI], +0.68% [0.21%-1.20%]; NNH, 147)
and 2397 patients receiving dual antiplatelet treatment of aspirin and clopidogrel (AOR, 1.47
[1.16-1.86]; absolute difference, +1.67% [0.58%-3.00%]; NNH, 60). The risk for in-hospital
mortality was similar between thosewhowere andwere not receiving antiplatelet therapy after
adjustment (8.0%vs 6.6%; AOR, 1.00 [0.94-1.06]; nonsignificant absolute difference, −0.01%
[−0.37% to0.36%]). However, patients receiving antiplatelet therapy had a greater
risk-adjusted likelihood of independent ambulation (42.1% vs 46.6%; AOR, 1.13 [1.08-1.17];
absolute difference, +2.23% [1.55%-2.92%]; number needed to treat, 43) and better functional
outcomes (modified Rankin Scale score, 0-1) at discharge (24.1% vs 27.8%; AOR, 1.14; 1.07-1.22;
absolute difference, +1.99% [0.78%-3.22%]; number needed to treat, 50).
CONCLUSIONS AND RELEVANCE Among patients with an acute ischemic stroke treated with
intravenous tPA, those receiving antiplatelet therapy before the stroke had a higher risk for
sICH but better functional outcomes than those whowere not receiving antiplatelet therapy.
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S troke is the second leading cause of death worldwide,with 5million people dying of stroke each year and an-other 5million left permanently disabled.1 Intravenous
tissue plasminogen activator (tPA) therapy improves out-
comes of acute ischemic stroke.2However, the use of tPA also
carries the risk for symptomatic intracranial hemorrhage
(sICH), the worst complication of thrombolysis for acute is-
chemic stroke. Approximately 40% of patients receive anti-
platelet therapybefore their stroke, and thesepatientsmaybe
at risk for increasedbleedingwithconcomitant tPAtreatment.3
Although the current US andEuropean guidelines do not pre-
clude administration of intravenous tPA in patients receiving
antiplatelet therapy before the stroke,2,4 uncertainties re-
main regarding the safety of thrombolysis in this population.
To date, the question whether patients receiving pre-
stroke antiplatelet therapyhave a substantially higher risk for
sICHremainsunanswered.5 Secondaryanalysis fromrandom-
ized clinical trials andobservational studies6-22 reported con-
flicting results. Many studies were limited in size and under-
powered to draw definite conclusions. Meta-analyses from
observational data23-25 were based on crude results without
accounting forbaselinedifferencesbetweenpatientswhowere
andwere not receiving antiplatelet therapy before the stroke.
Furthermore, data are scarce for various antiplatelet regi-
mens (withmost studies analyzing aspirinmonotherapyonly
without including nonaspirin antiplatelet drugs or combina-
tiontherapy), forclinically relevantsubgroups (thoseolder than
80 years; women; and patients with a history of coronary ar-
tery disease or prior stroke orwith awindow of 3.0-4.5 hours
for treatment), and for clinical outcomes with tPA after anti-
platelet therapy.
Using data from the American Heart Association and
American Stroke Association GetWith the Guidelines–Stroke
(GWTG-Stroke) program,we evaluated the safety and clinical
outcomes among patients with intravenous tPA who re-
ceivedantiplatelet therapy in routineclinicalpractice.Our spe-
cific goalswere to (1) determinewhetherpatients receivingan-
tiplatelet therapywere at an increased risk for sICH after tPA,
(2) evaluate the safety profile in clinically relevant sub-
groups, and (3) investigate the association of prior antiplate-
let therapy with clinical outcomes.
Methods
GWTG-Stroke Registry
TheGWTG-Strokeprogramincludesanongoing,voluntary,na-
tional stroke registry sponsored by the American Heart Asso-
ciation and American Stroke Association. Details of the de-
sign and conduct of the GWTG-Stroke registry have been
described previously.26,27 Standardized data collection in the
GWTG-Stroke registry includes patient demographics, medi-
cal history, diagnostic testing, brain imaging, in-hospital treat-
ment, and outcomes. As of January 1, 2009, the GWTG-
Stroke registry collects data on medications used before
admission, includingantiplatelet agentsoranticoagulants.The
validity and reliability of data collection in the GWTG-Stroke
registry has been reported in previous research.28 Quintiles,
Inc serves as the data collection and coordination center for
the GWTG-Stroke registry. The Duke Clinical Research Insti-
tute serves as the data analysis center and has an agreement
to analyze the aggregate deidentified data for research pur-
poses. This study was approved by the institutional review
board of Duke University.
Study Population
The initial population included 113 394patientswith acute is-
chemic stroke who received intravenous tPA alone and not
combinedwith endovascular treatment inGWTG-Strokehos-
pitals from January 1, 2009, through March 31, 2015. We ex-
cludedpatientswhohadmissing informationon theuseof an-
tiplatelet agents before admission, patientswhohad received
tPA beyond (>4.5 hours after onset of stroke symptoms) the
guideline-recommendedtreatmentwindow,2andpatientswho
were transferred in or out because in-hospital care and out-
comes could not be tracked after interhospital transfer. After
these exclusions, our primary study population consisted of
85 072 patients from 1545 hospitals in the United States
(Figure 1). The characteristics of patients included and ex-
cluded are shown in eTable 1 in the Supplement.
Study Variables
Antiplatelet therapy was defined as documentation of pa-
tients taking an antiplatelet medication within 7 days before
hospital arrival. Startingwith the October 2012 version of the
data collection form, specific antiplatelet agents, such as as-
pirin or the combination of aspirin and dipyridamole, clopi-
dogrel, ticlopidine, or others,were recorded. Prasugrel and ti-
cagrelor were added to the October 2013 version of the data
collection form. Based on these data, we further categorized
antiplatelet therapy in these lateryears into the following4mu-
tually exclusive groups: (1) aspirin alone, (2) a combination of
Figure 1. Study Population
113 394 Patients identified in the GWTG-Stroke registry
with acute ischemic stroke and receiving
intravenous tPA from January 1, 2009, to
March 31, 2015
28 322 Excluded
8047 Transferred in, transferred out, or
no discharge information
3348 No tPA complications information
145 Intravenous tPA administered at
an outside hospital
5531 Investigational or experimental
protocol for thrombolysis
3056 Missing treatment times
24 No information on sex
4961 No antiplatelet therapy information
1310 INR >1.7 or no INR information in patients
receiving prior anticoagulant therapy
1900 > 4.5 h After stroke onset
Preadmission antiplatelet therapy
85 072 Patients in the primary analysis (1545 hospitals)
38 844
46 228 No preadmission antiplatelet therapy
INR indicates international normalized ratio; GWTG-Stroke, American Heart
Association and American Stroke Association GetWith the Guidelines–Stroke
program; and tPA, tissue plasminogen activator.
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aspirin and dipyridamole, (3) clopidogrel alone, and (4) dual
antiplatelet therapy with aspirin and clopidogrel. Ticlopi-
dine, prasugrel, ticagrelor, unknown antiplatelet agents, or
other combinationswerenot analyzed separatelyowing to the
small sample size (n = 278).
The primary end points were sICH, in-hospital mortality,
discharge ambulatory status, and the modified Rankin Scale
(mRS) score (range, 0 [no symptoms] to 6 [death]). The sICH
was defined as an intracranial hemorrhage within 36 hours,
documented by computed tomography or magnetic reso-
nance imaging and the treating physician’s notes indicating
clinical deterioration attributable to hemorrhage.29,30 Func-
tional outcome measured by the mRS score was reported
among patients treated with intravenous tPA fromOctober 1,
2012, toMarch 31, 2015, and further dichotomized as0 to 1 for
excellent recovery and0 to2 for functional independence.31,32
The characteristics of patientswith orwithout a documented
mRS score at discharge are shown in eTable 2 in the Supple-
ment. Secondary end points included life-threatening or
serious systemic hemorrhage within 36 hours, any tPA com-
plication within 36 hours (sICH, life-threatening or serious
systemichemorrhage,orother seriouscomplications), anddis-
charge destination (home, hospice, inpatient rehabilitation
facility, or skilled nursing facility).
Statistical Analysis
Data were analyzed from January 1, 2009, throughMarch 31,
2015. Means (SDs) and medians (25th-75th percentiles) were
used todescribe thedistributionof continuousvariables; per-
centages described categorical variables.We compared base-
line characteristics between patients with and without anti-
platelet therapy using the Pearson χ2 test for categorical
variables and theWilcoxon rank sum test for continuous vari-
ables. Multivariable logistic regression analyses investigated
the associations between prior antiplatelet therapy and each
outcome. These analyses adjusted for baseline patient demo-
graphic and clinical variables and hospital-level factors that
are expected to be predictive of outcome and have been used
inpriorGWTG-Stroke analyses.29,33 Patient-level variables in-
cluded age; sex; race; baseline National Institutes of Health
Stroke Scale (NIHSS) score34 (a measure of neurologic defi-
cits; range, 0-42,with a higher score indicating greater stroke
severity); systolic blood pressure; serum glucose level; time
from arrival to initiation of tPA (door-to-needle time); medi-
cal history of atrial fibrillation, coronary artery disease, prior
stroke or transient ischemic attack, carotid stenosis, hyper-
tension, diabetesmellitus, dyslipidemia, or peripheral vascu-
lar disease; smoking status; use of emergency medical ser-
vices transport; arrival time during regular working hours
(7 AM to 6 PM Monday through Friday); and use of an antico-
agulant before admission. We also examined the interaction
between prior use of antiplatelet agents and anticoagulants.
Hospital-level factors included hospital bed size, academic
status, primary stroke center status, annual ischemic stroke
volume,meannumberofpatients treatedwith intravenous tPA
annually, hospital region, and rural location. These analyses
accounted for within-hospital clustering using generalized
estimating equations.
The number needed to treat (NNT) or to harm (NNH)was
reported to establish the balance of benefits and harms of ad-
ministering tPA topatientswithprioruseof antiplatelet agents
comparedwith those treatedwith tPAwithoutprior useof an-
tiplatelet agents. Calculation of the absolute difference was
basedon theestimatedmeanprobabilityof theoutcome in the
population if all patients received antiplatelet therapy before
tPA administration minus the probability of the outcomes if
noneof them received antiplatelet agents basedon the covar-
iates in the logistic regressionmodel.35Apositive absolutedif-
ference would indicate that this outcome was more frequent
in patients treated with tPA who had received antiplatelet
therapybefore the stroke. Thismethodhas the theoretical ad-
vantage of translating the odds ratio (OR) froma relative scale
into a clinically meaningful measure of the treatment effect
in an absolute scale while adjusting for possible imbalance in
prognostically important baseline characteristics.
Because theNIHSS score is a critical predictor of outcomes
in acute ischemic stroke and sICH after tPA, we used a mul-
tiple imputation method to impute missing NIHSS values. A
sensitivityanalysiswasperformedafterexcludingpatientswith
missing NIHSS data (4229 [5.0%]). The characteristics of all
85 072 patients (including those without NIHSS scores re-
corded) and only the 80843 patients with the NIHSS score re-
cordedareshownineTable3 in theSupplement.Wealsoevalu-
ated the associationwith sICH in clinically relevant subgroups
by age (≤80 and >80 years) according to the European Coop-
erativeAcuteStrokeStudy (ECASS) I through III criteria and the
European license for the study drug,32,36,37 sex, medical his-
tory of coronary artery disease, prior stroke and/or transient
ischemic attack, guideline-recommended treatmentwindows
(class I level of evidence A, within 3.0 hours; class I level of
evidence B, 3.0-4.5 hours),2 and various antiplatelet regi-
mens, including aspirin alone, clopidogrel alone, aspirin-
dipyridamole,andaspirin-clopidogreldualantiplatelet therapy.
All P values are 2 sided, with P < .05 considered statisti-
cally significant. All statistical analyseswereperformedusing
STATA software (version 14.0; StataCorp, LP).
Results
Among 85 072 patients receiving intravenous tPA, 38 844
(45.7%)wereusing antiplatelet therapybefore admission and
46228 (54.3%)were not. Table 1 displays demographic, clini-
cal, and hospital characteristics according to prestroke anti-
platelet use. Patients receiving antiplatelet therapy before
admission were older (median [25th-75th percentile] age, 76
[65-84] vs 68 [56-80] years), had a greater prevalence of car-
diovascular risk factors, andweremore likely to receive anti-
hypertensives or medications to lower cholesterol or glucose
levels but were less likely to receive anticoagulants before
admission (P < .001 for all). The initial NIHSS score (median
[25th-75th percentile], 10 [5-17] vs 10 [5-16]; P < .001) was
slightly higher in patients receiving antiplatelet agents be-
fore stroke. Because of the large sample size, the P value was
statistically significant, but themeasureddifference inNIHSS
scores was relatively small.
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Table 1. Patient and Hospital Characteristics According to Preadmission Use of Antiplatelet Therapy
Variable
Preadmission Antiplatelet Therapya
P Value
Yes
(n = 38 844)
No
(n = 46 228)
Age, y
Mean (SD) 73.7 (13.2) 67.2 (15.7)
<.001
Median (25th-75th percentile) 76 (65-84) 68 (56-80)
Women 19 293 (49.7) 23 768 (51.4) <.001
Race or ethnicity, No. (%)
White 29 338 (75.6) 31 219 (67.6)
<.001
Black 4835 (12.5) 7848 (17.0)
Asian 2352 (6.1) 3824 (8.3)
Hispanic 894 (2.3) 1380 (3.0)
Other 1399 (3.6) 1916 (4.1)
History, No. (%)
Atrial fibrillation or flutter 9986 (25.7) 7720 (16.7) <.001
Prosthetic heart valve 496 (1.3) 419 (0.9) <.001
Previous stroke and/or transient ischemic attack 14 246 (36.7) 7289 (15.8) <.001
Carotid stenosis 1677 (4.3) 604 (1.3) <.001
Coronary artery disease and/or myocardial infarction 14 781 (38.1) 6300 (13.6) <.001
Heart failure 4834 (12.4) 3009 (6.5) <.001
Hypertension 31 873 (82.1) 30 499 (66.0) <.001
Dyslipidemia 21 116 (54.4) 14 746 (31.9) <.001
Peripheral vascular disease 2044 (5.3) 983 (2.1) <.001
Diabetes mellitus 12 489 (32.2) 10 122 (21.9) <.001
Smoker 5349 (13.8) 9588 (20.7) <.001
Medications used before admission, No. (%)
Antiplatelet agent 38 844 (100) 0 NA
Anticoagulant 1449 (3.7) 3318 (7.2) <.001
Antihypertensive 29 610 (83.2) 23 373 (53.9) <.001
Cholesterol level reducer 23 181 (59.7) 11 859 (25.7) <.001
Glucose level reducer 9258 (26.5) 6503 (15.1) <.001
Mode of arrival, EMS vs other, No. (%) 31 235 (83.4) 36 722 (82.4) <.001
Off-hour presentation, No. (%)b 18 842 (48.5) 22 634 (49.0) .19
NIHSS scorec
Mean (SD) 11.5 (7.6) 11.2 (7.4)
<.001Median (25th-75th percentile) 10 (5-17) 10 (5-16)
Missing 1820 (4.7) 2409 (5.2)
Time from symptom onset to tPA treatment, median (25th-75th percentile), min 138 (108-170) 138 (107-172) .11
Door-to-needle time, median (25th-75th percentile), min 68 (52-90) 68 (51-91) .94
Heart rate, beats/min
Mean (SD) 80.4 (17.9) 83.4 (18.6)
<.001
Median (25th-75th percentile) 78 (68-90) 81 (70-94)
Blood pressure, mm Hg
Systolic
Mean (SD) 156.8 (28.3) 157.5 (28.9)
.03
Median (25th-75th percentile) 155 (138-175) 155 (138-176)
Diastolic
Mean (SD) 83.2 (18.2) 86.4 (18.9)
<.001
Median (25th-75th percentile) 82 (71-94) 85 (74-97)
Creatinine level, mg/dL
Mean (SD) 1.4 (4.3) 1.3 (4.0)
<.001
Median (25th-75th percentile) 1.0 (0.9-1.3) 1.0 (0.8-1.2)
(continued)
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Symptomatic Intracranial Hemorrhage
Overall, 3647 patients (4.3%) developed an sICH after intra-
venous tPA administration. Patients receiving antiplatelet
therapyhadahigher crude rate of sICH (5.0%) than thosewho
werenot receivingantiplatelet therapybefore thestroke (3.7%)
(Table 2). After risk adjustment, antiplatelet therapy was in-
dependently associatedwithhigheroddsof sICH (adjustedOR
[AOR], 1.18; 95% CI, 1.10-1.28), although the absolute excess
risk was small (absolute difference +0.68% [95% CI, 0.36%-
1.01%]; NNH, 147). No interaction effect was found between
prior antiplatelet andanticoagulant therapies (P = .81). Theas-
sociationbetweenantiplatelet therapy and sICH remainedes-
sentially unchanged after excluding patients with missing
NIHSS data (AOR, 1.17 [95% CI, 1.09-1.27]; absolute differ-
ence, +0.62% [95%CI, 0.30%-0.96%];NNH, 161). Analyses of
clinically relevant subgroups by age (≤80 and>80years), sex,
medical history of coronary artery disease, prior stroke, and
treatmentwindow (within 3.0 and 3.0-4.5 hours) found simi-
lar trends of higher risk for sICH associated with prior use of
antiplatelet agents (Figure 2), although thedifferencewasnot
statistically significant for patientswho received tPA from3.0
to 4.5 hours after acute ischemic stroke.
Of the 43 034 patients enrolled from October 1, 2012, to
March31, 2015, 22 813 (53.0%) receivednoantiplatelet agents.
Among the 20221 patients who received antiplatelet agents,
15 116 (35.1%) received aspirin alone; 2397 (5.6%), aspirin-
clopidogrel dual antiplatelet therapy; 2037 (4.7%), clopido-
grel alone; 393 (0.9%), aspirin-dipyridamole; and 278 (0.6%),
other or unknownantiplatelet agents. The crude rates of sICH
werehighestamongpatients receivingaspirin-clopidogreldual
antiplatelet therapy (131 of 2397 [5.5%]), followed by aspirin
alone (698 of 15 116 [4.6%]), clopidogrel alone (71 of 2037
[3.5%]), no antiplatelet therapy (760 of 22 813 [3.3%]), and
aspirin-dipyridamole (9 of 393 [2.3%]). After risk adjustment,
aspirin alone (AOR, 1.19 [95% CI, 1.06-1.34]; absolute differ-
ence, +0.68% [95% CI, 0.21%-1.20%]; NNH, 147) and aspirin-
clopidogrel dual antiplatelet therapy (AOR, 1.47 [95%CI, 1.16-
1.86]; absolute difference, +1.67% [95% CI, 0.58%-3.00%];
NNH, 60) were associatedwith increased odds for sICH com-
paredwithnouse of antiplatelet therapy (Figure 2).We found
no statistically significant differences in the use of clopido-
grel alone (AOR, 0.85 [95% CI, 0.65-1.12]; nonsignificant
absolute difference, −0.54% [95% CI, −1.30% to 0.43%]) or
aspirin-dipyridamole (AOR, 0.56 [95% CI, 0.28-1.12]; nonsig-
nificantabsolutedifference,−1.66%[95%CI,−2.76%to0.42%])
compared with no use of antiplatelet agents.
In-Hospital Mortality, Ambulatory Status, andmRS Score
at Discharge
Despite higher bleeding rates, prior antiplatelet therapy was
not associated with in-hospital mortality after risk adjust-
ment (unadjustedrates,8.0%vs6.6%;AOR,1.00[95%CI,0.94-
1.06]; nonsignificant absolute difference, −0.01% [95% CI,
−0.37%to0.36%]) (Table2). Incontrast,patients receivingpre-
stroke antiplatelet therapy had greater odds of being able to
ambulate independently at discharge after adjustment (unad-
justed rates, 42.1%vs46.6%;AOR, 1.13 [95%CI, 1.08-1.17]; ab-
solute difference, +2.23% [95% CI, 1.55%-2.92%]; NNT, 43).
Among patients with a documented mRS score, prestroke
antiplatelet therapywas associatedwith favorable functional
outcomes at discharge after risk adjustment formRS scores of
0 to 1 (unadjusted rates, 24.1% vs 27.8%; AOR, 1.14 [95% CI,
1.07-1.22]; absolute difference, +1.99% [95% CI, 0.78%-
3.22%];NNT,50)andformRSscoresof0to2 (unadjustedrates,
Table 1. Patient and Hospital Characteristics According to Preadmission Use of Antiplatelet Therapy (continued)
Variable
Preadmission Antiplatelet Therapya
P Value
Yes
(n = 38 844)
No
(n = 46 228)
Serum glucose level, mg/dL
Mean (SD) 138.6 (60.8) 135.6 (60.4)
<.001
Median (25th-75th percentile) 120 (103-152) 117 (102-146)
Body mass indexd
Mean (SD) 28.4 (7.4) 28.5 (7.2)
.18
Median (25th-75th percentile) 27.3 (23.9-31.6) 27.4 (23.9-31.8)
Hospital characteristics
No. of beds, median (25th-75th percentile) 382 (264-579) 391 (268-584) .001
Annual ischemic stroke volume, median (25th-75th percentile), No. of patients 227 (156-349) 224 (157-346) .04
Annual No. of IV tPA cases, median (25th-75th percentile) 21 (12-32) 21 (13-32) .03
Academic hospital, No. (%) 23 878 (62.5) 28 433 (62.4) .78
Joint Commission primary stroke center, No. (%) 20 072 (51.7) 23 599 (51.0) .07
Rural hospital, No. (%) 1341 (3.5) 1273 (2.8) <.001
Abbreviations: EMS, emergencymedical services; IV tPA, intravenous tissue
plasminogen activator; NA, not applicable; NIHSS, National Institutes of Health
Stroke Scale.
SI conversion factors: To convert creatinine to micromoles per liter, multiply by
88.4; glucose tomillimoles per liter, multiply by 0.0555.
a Owing tomissing data, totals may not match the numbers in the column
headings.
b Indicates anytime outside of 7 AM to 6 PM on weekdays.
c Scores range from0 to 42, with a higher score indicating greater stroke
severity.
d Calculated as weight in kilograms divided by height in meters squared.
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32.8% vs 37.3%; AOR, 1.16 [95% CI, 1.09-1.24]; absolute dif-
ference, +2.54% [95% CI, 1.33%-3.77%]; NNT, 39). These as-
sociated benefits in functional outcomes were consistent in
patients receiving aspirin alone (Table 3). Similar improve-
ments in ambulatory status and mRS scores were also ob-
served after risk adjustment among patients receiving clopi-
Table 2. Primary and Secondary End Points According to Preadmission Use of Antiplatelet Therapy
End Point
No. of Events/Total No. of Patients (%) OR (95% CI)
P Value
Preadmission
Antiplatelet Therapy
No Preadmission
Antiplatelet Therapy Unadjusted Adjusteda
Primary
sICH 1927/38 844 (5.0) 1720/46 228 (3.7) 1.35 (1.26-1.44) 1.18 (1.10-1.28) <.001
In-hospital mortality 3115/38 844 (8.0) 3061/46 228 (6.6) 1.23 (1.17-1.29) 1.00 (0.94-1.06) .95
Independent ambulation
at dischargeb
14 277/33 880 (42.1) 18 825/40 432 (46.6) 0.84 (0.81-0.86) 1.13 (1.08-1.17) <.001
mRS score at dischargec
0-1 3730/15 475 (24.1) 4892/17 613 (27.8) 0.83 (0.79-0.87) 1.14 (1.07-1.22) <.001
0-2 5081/15 475 (32.8) 6548/17 613 (37.2) 0.83 (0.79-0.86) 1.16 (1.09-1.24) <.001
Secondary end points
Life-threatening or serious
systemic hemorrhage
451/38 844 (1.2) 314/46 228 (0.7) 1.72 (1.49-1.99) 1.45 (1.23-1.72) <.001
Any tPA complicationd 3509/38 844 (9.0) 3497/46 228 (7.6) 1.21 (1.16-1.27) 1.08 (1.02-1.14) .008
Discharge to home 16 070/38 844 (41.4) 21 098/46 228 (45.6) 0.84 (0.82-0.86) 1.13 (1.09-1.17) <.001
Discharge to hospice 2446/38 844 (6.3) 2128/46 228 (4.6) 1.39 (1.31-1.48) 0.97 (0.90-1.04) .37
Discharge to skilled
nursing facilityb
6728/38 784 (17.3) 6398/46 138 (13.9) 1.30 (1.26-1.35) 0.98 (0.94-1.02) .29
Discharge to inpatient
rehabilitation facilityb
9741/38 784 (25.1) 12 627/46 138 (27.4) 0.89 (0.86-0.92) 0.93 (0.90-0.97) <.001
Abbreviations: mRS, modified Rankin Scale; OR, odds ratio; sICH, symptomatic
intracranial hemorrhage; tPA, tissue plasminogen activator.
a Adjustment for patient-level characteristics includes age; sex; race; systolic
blood pressure; serum glucose level; baseline National Institutes of Health
Stroke Scale score; door-to-needle time; medical history of atrial fibrillation or
flutter, prior stroke and/or transient ischemic attack, coronary artery disease
and/or myocardial infarction, heart failure, carotid stenosis, hypertension,
dyslipidemia, diabetes mellitus, or peripheral vascular disease; smoking status;
emergencymedical services arrival; on- or off-hour presentation; and
preadmission anticoagulant use. Adjustment for hospital-level characteristics
includes number of beds, academic status, primary stroke center, annual
ischemic stroke volume, annual tPA volume, hospital region, and rural location.
No significant interaction between preadmission anticoagulant and
antiplatelet agent use was observed.
b Excludes missing data.
c Indicates fromOctober 1, 2012, throughMarch 31, 2015. Scores range from
0 (no symptoms) to 6 (death). Excludes patients with missing mRS scores.
Characteristics between patients with and without documentedmRS scores
are shown in eTable 1 in the Supplement.
d Includes sICHwithin 36 hours, life-threatening or serious systemic
hemorrhage within 36 hours, or other serious complications.
Figure 2. Preadmission Antiplatelet Therapy and Symptomatic Intracranial Hemorrhage (sICH)
0.2 0.8 2.01.81.61.41.20.6 1.0
AOR (95% CI)
0.4
Favors
antiplatelet
therapy
Favors no
antiplatelet
therapy
sICH Event, No. (%)
Yes NoPreadmission Antiplatelet Therapy AOR (95% CI)
1927/38 844 (5.0) 1720/46 228 (3.7)Overall 1.18 (1.10-1.28)
1607/32 418 (5.0) 1387/37 938 (3.7)Treatment window within 3.0 h 1.22 (1.12-1.32)
320/6426 (5.0) 333/8290 (4.0)Treatment window 3.0-4.5 h 1.05 (0.87-1.25)
908/13 927 (6.5) 619/11 043 (5.6)Age >80 y 1.18 (1.06-1.32)
1019/24 917 (4.1) 1101/35 185 (3.1)Age ≤80 y 1.19 (1.08-1.32)
995/19 293 (5.2) 909/23 768 (3.8)Women 1.19 (1.08-1.31)
932/19 551 (4.8) 811/22 460 (3.6)Men 1.18 (1.06-1.32)
762/14 781 (5.2) 269/6300 (4.3)History of CAD and/or MI 1.33 (1.13-1.55)
1165/24 044 (4.8) 1450/39 894 (3.6)No history of CAD and/or MI 1.13 (1.03-1.23)
709/14 246 (5.0) 323/7289 (4.4)History of stroke and/or TIA 1.17 (1.02-1.34)
1218/24 579 (5.0) 1396/38 905 (3.6)No history of stroke and/or TIA 1.19 (1.09-1.30)
698/15 116 (4.6) 760/22 813 (3.3)Aspirina 1.19 (1.06-1.34)
9/393 (2.3) 760/22 813 (3.3)Aspirin-dipyridamolea 0.56 (0.28-1.12)
71/2037 (3.5) 760/22 813 (3.3)Clopidogrela 0.85 (0.65-1.12)
131/2397 (5.5) 760/22 813 (3.3)Aspirin-clopidogrel dual antiplatelet therapya 1.47 (1.16-1.86)
Data are given overall and in clinically relevant subgroups. AOR indicates
adjusted odds ratio; CAD, coronary artery disease; MI, myocardial infarction;
and TIA, transient ischemic attack.
a Includes patients admitted October 1, 2012, or later.
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dogrel alone or aspirin-clopidogrel dual antiplatelet therapy,
although none of these differences reached statistical
significance.
Secondary Outcomes
The rates of life-threatening or serious sICHand any tPA com-
plications were higher in patients receiving prior antiplatelet
therapy (Table 2). In the unadjusted analysis, fewer patients
who received antiplatelet therapy were discharged home
(41.4% vs 45.6%). However, they had higher AORs for being
discharged home than patients without antiplatelet use (1.13
[95%CI, 1.09-1.17]).Nostatistically significantdifferenceswere
seen in discharge to hospice (unadjusted rates, 6.3% vs 4.6%;
AOR,0.97 [95%CI,0.90-1.04]) or a skillednursing facility (un-
adjusted rates, 17.3% vs 13.9%; AOR, 0.98 [95% CI, 0.94-
1.02]) between the two groups.
Discussion
In this large, nationwide, contemporary registry of patients
with acute ischemic stroke, we found that the use of intrave-
nous tPA in patients receiving prestroke antiplatelet therapy
was associatedwith an increased risk for sICHcomparedwith
tPA-treated patients without prior antiplatelet therapy. De-
spite higher rates of intracranial bleeding, the overall excess
risk appeared small (absolute difference, +0.68%; NNH, 147)
anddidnot translate intohigher in-hospitalmortality. In con-
trast, patients treated with tPA after antiplatelet therapy ap-
peared to have better functional outcomes in terms of ambu-
latory status (NNT, 43) andmRS scores of 0 to 1 (NNT, 50) and
0 to 2 (NNT, 39) than those not receiving antiplatelet therapy.
Collectively, these findings demonstrate that the risk for sICH
among patients with stroke who receive antiplatelet therapy
before the stroke and are treatedwith intravenous tPA is rela-
tively lowandmust beweighed against the potential benefits
in terms of improved functional outcomes.
Intravenous tPA remains the only available pharmaco-
logic therapy to improve the outcomes for acute ischemic
stroke. However, experience with tPA in patients with acute
ischemic strokewho receiveantiplatelet therapyhasbeen lim-
ited. Subgroupanalysesof theNational InstituteofNeurologi-
cal Disorder and Stroke tPA Stroke Trial6 (ORs not reported)
and the ECASS III Trial7 (unadjusted OR, 1.12) showed no as-
sociationbetweenpreadmissionantiplatelet therapyandsICH.
In contrast, rates of sICHwere significantly higher among an-
tiplatelet therapy users in the Stroke-Acute Ischemic NXY
Treatment (SAINT I and II) trials9 (AORs, 2.04 for single and
9.19 for double antiplatelet therapy) and the Third Interna-
tional Stroke Trial8 (IST-3; AOR, 1.62). Patients were not ran-
domized based on their antiplatelet drug use in any of these
secondaryanalysesof the trial data. Theseposthoc trial analy-
ses were performed in relatively small numbers of patients
comparedwith our study, in highly selected clinical trial par-
ticipants, and inanerawhenaspirinmonotherapywouldhave
been the predominant antiplatelet drug used. Findings from
small andmoderately poweredobservational studies showed
that the odds of sICH range from0.6 to 6.0.11-20 However, the
reported sICH risk might have been underestimated or over-
estimated, especially when the sample size was small and no
riskadjustmentwasmade.ApreviousGWTG-Strokeanalysis29
failed to identify antiplatelet therapy as an independent pre-
dictor of sICH, likely owing to its smaller sample size. This re-
sult highlights the need for large studies to obtain stable esti-
mates of bleeding risks in patients treated with tPA after use
of antiplatelet therapy.
This study represents, to our knowledge, one of the
largest clinical experiences of intravenous tPA available so
far. Among 85 072 patients with ischemic stroke treated
with tPA, 38 844 had received antiplatelet drugs before
stroke onset. In accordance with other multicenter registry
reports, such as the Safe Implementation of Thrombolysis in
Stroke–Monitoring Study (SITS-MOST)14 and the Interna-
tional Stroke Thrombolysis Registry (SITS-ISTR),11 we found
that antiplatelet therapy was associated with a higher inci-
dence of sICH. However, patterns of care and administration
of tPA in the United States may differ from those of other
nations. Although the off-label use of tPA in the elderly is
increasing in Europe after publication of the findings of the
IST-3 trial,38 the European license still excludes patients
older than 80 years. The SITS-ISTR included a subgroup of
patients who were treated off-label; however, patients older
than 80 years or those who received treatment beyond the
3.0-hour time window were specifically excluded from the
analysis.11 We included patients with a class I level of evi-
dence B recommendation for tPA (treatment window, 3.0-
4.5 hours), those 80 years or older, women, and those with
a medical history of coronary artery disease or a prior stroke
and found similar associations between prestroke antiplate-
let therapy and sICH in each clinically relevant subgroup.
Table 3. Primary End Points According to Various Preadmission Antiplatelet Therapy Regimensa
Outcomeb
Antiplatelet Therapy, OR (95% CI)
Aspirin Alone
Aspirin-
Dipyridamole Clopidogrel Alone
Aspirin-Clopidogrel
Dual Antiplatelet
Therapy
sICH 1.19 (1.06-1.34) 0.56 (0.28-1.12) 0.85 (0.65-1.12) 1.47 (1.16-1.86)
In-hospital mortality 0.97 (0.88-1.07) 1.10 (0.72-1.69) 1.04 (0.85-1.27) 0.98 (0.80-1.19)
Independent ambulation
at discharge
1.09 (1.03-1.15) 1.04 (0.82-1.33) 1.13 (1.00-1.28) 1.08 (0.96-1.21)
mRS score at dischargec
0-1 1.16 (1.07-1.26) 0.59 (0.40-0.85) 1.09 (0.92-1.29) 1.07 (0.91-1.25)
0-2 1.16 (1.08-1.25) 0.80 (0.58-1.11) 1.11 (0.95-1.30) 1.15 (0.98-1.34)
Abbreviations: mRS, modified
Rankin Scale; OR, odds ratio;
sICH, symptomatic intracranial
hemorrhage; tPA, tissue plasminogen
activator.
a Indicates fromOctober 1, 2012, to
March 31, 2015.
b Compared with patients treated
with tPA without prior use of
antiplatelet therapy.
c Scores range from0 (no symptoms)
to 6 (death).
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Given the high prevalence of coronary artery disease and
the widespread use of percutaneous coronary intervention,
manypatients are receivingaspirinordual antiplatelet therapy
at the time of stroke onset. To date, only a few studies have
investigated the association between sICH and different an-
tiplatelet regimens.9-11,16,18 In our analysis of 20 221 patients
receivingdifferentantiplatelet regimens, the incidenceof sICH
was thehighest inpatientsusingdual antiplatelet therapy.This
observationmaynotbe surprisinggiven that aspirin andclopi-
dogrel decreaseplatelet aggregationand inhibit thrombus for-
mationby targetingmore than1pathway in thehemostatic cas-
cade and hence likely increase the risk for bleeding after tPA
administration. Despite higher sICH rates, the overall excess
riskappeared tobesmall. Forevery 147patients receiving long-
term antiplatelet drugs and treated with tPA, only 1 addi-
tional sICH occurred compared with those without prior an-
tiplatelet therapy. Even among patients receiving dual
antiplatelet therapy, only 1 more sICH occurred for every 60
patients treated with tPA. The relatively small excess risk did
not translate into highermortality. In contrast, we found pre-
admission antiplatelet use was associated with better func-
tional outcomes asmeasured by discharge ambulatory status
andmRS scores. The NNTs were 43 for independent ambula-
tionand50 for excellent functional recovery (mRSscores,0-1).
Therefore, the overall benefit of tPA likely will outweigh any
risk for excess bleeding associated with antiplatelet therapy.
Our studyhas limitations.First,weperformeda retrospec-
tiveobservationalanalysis.Unmeasuredconfoundingandtreat-
ment selection may bias outcome comparisons. However, pa-
tients receiving antiplatelet drugs were older and had more
cardiovascular risk factors than those not receiving antiplate-
let therapy before the stroke. Therefore, selection bias, if it ex-
ists, might bemore likely to be against patients receiving anti-
platelet therapy.Second,strokeseverity isacriticaldeterminant
of stroke outcomes.35Wemay have introduced bias by using a
multiple imputation method for patients without a record of
NIHSSscores (5.0%).Nonetheless,NIHSSscoresappeared tobe
missing at random because patients with documented NIHSS
scores were comparable to those patients without docu-
mented NIHSS scores with respect to most characteristics. A
sensitivityanalysisof the tPAcohortwithcompleteNIHSSdata
found consistent results.
Third, we did not have access to data on the time and the
last dose of the antiplatelet drug or themedication indication
forwhichtheantiplateletdrugwasprescribedbefore thestroke.
As a result, thebleeding risksmight beunderestimated for pa-
tients taking antiplatelet drugs up to the day of the stroke or
overestimated for patients who stopped therapy for reasons
such as surgical procedures or nonadherence and subse-
quently had an ischemic stroke event. Fourth, sICH was not
centrallyadjudicatedandwasbasedonlocally interpretedcom-
puted tomographic or magnetic resonance imaging findings.
TheGWTG-Stroke registrydoesnothave the actual images for
review. Therefore, comparing the incidence of sICHwith that
of other studies may be difficult. Fifth, we were unable to re-
port long-term functional outcomes because thesemeasures
are not currently collected in the GWTG-Stroke registry.
Nonetheless, our study was able to report discharge destina-
tion, ambulatory status, and mRS scores, which have strong
associationswith long-termfunctional outcomesat90days.39
Last, theGWTG-Stroke registry is a voluntary program.These
results might not be extrapolated to patients treated in
non–GWTG-Stroke registry hospitals or in other countries.
Conclusions
This study represents the largest clinical experience of stroke
thrombolysis in patients receiving antiplatelet therapy before
stroke onset. The use of intravenous tPA in patients receiving
antiplatelet therapywasassociatedwithslight increasedrisk for
sICH, especially among patients receiving aspirin or dual anti-
platelet therapy. However, the relatively small excess risk did
not translate into higher mortality and appeared to be associ-
ated with favorable functional outcomes at discharge. There-
fore, the overall benefits of thrombolytic therapy may out-
weightherisks ineligiblepatientswith ischemicstrokereceiving
antiplatelet therapy before stroke onset.
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